JP6767368B2 - 抗癌性組成物 - Google Patents

抗癌性組成物 Download PDF

Info

Publication number
JP6767368B2
JP6767368B2 JP2017529637A JP2017529637A JP6767368B2 JP 6767368 B2 JP6767368 B2 JP 6767368B2 JP 2017529637 A JP2017529637 A JP 2017529637A JP 2017529637 A JP2017529637 A JP 2017529637A JP 6767368 B2 JP6767368 B2 JP 6767368B2
Authority
JP
Japan
Prior art keywords
arn
solid dispersion
poly
meth
acrylate copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536401A5 (enExample
JP2017536401A (ja
Inventor
ヴァーレック，ガート
Original Assignee
アラゴン ファーマシューティカルズ，インコーポレイテッド
アラゴン ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6767368(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アラゴン ファーマシューティカルズ，インコーポレイテッド, アラゴン ファーマシューティカルズ，インコーポレイテッド filed Critical アラゴン ファーマシューティカルズ，インコーポレイテッド
Publication of JP2017536401A publication Critical patent/JP2017536401A/ja
Publication of JP2017536401A5 publication Critical patent/JP2017536401A5/ja
Application granted granted Critical
Publication of JP6767368B2 publication Critical patent/JP6767368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017529637A 2014-12-05 2015-12-03 抗癌性組成物 Active JP6767368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05
EP14196591.3 2014-12-05
PCT/US2015/063667 WO2016090101A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (3)

Publication Number Publication Date
JP2017536401A JP2017536401A (ja) 2017-12-07
JP2017536401A5 JP2017536401A5 (enExample) 2019-01-17
JP6767368B2 true JP6767368B2 (ja) 2020-10-14

Family

ID=52006905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529637A Active JP6767368B2 (ja) 2014-12-05 2015-12-03 抗癌性組成物

Country Status (31)

Country Link
US (3) US20170360707A1 (enExample)
EP (2) EP3842034B1 (enExample)
JP (1) JP6767368B2 (enExample)
KR (1) KR102348325B1 (enExample)
CN (2) CN106999430A (enExample)
AR (1) AR102924A1 (enExample)
AU (1) AU2015358493B2 (enExample)
CA (1) CA2969661C (enExample)
CL (1) CL2017001372A1 (enExample)
CO (1) CO2017005573A2 (enExample)
CR (1) CR20170217A (enExample)
CY (1) CY1123856T1 (enExample)
DK (1) DK3226842T3 (enExample)
EA (1) EA035988B1 (enExample)
ES (2) ES2839128T3 (enExample)
HR (1) HRP20201902T1 (enExample)
HU (1) HUE051888T2 (enExample)
IL (1) IL252324B (enExample)
LT (1) LT3226842T (enExample)
MA (2) MA55404A (enExample)
MD (1) MD3226842T2 (enExample)
MX (1) MX384382B (enExample)
NI (1) NI201700069A (enExample)
PL (1) PL3226842T3 (enExample)
PT (1) PT3226842T (enExample)
RS (1) RS61466B1 (enExample)
SG (1) SG11201704264UA (enExample)
SI (1) SI3226842T1 (enExample)
TW (1) TWI683662B (enExample)
UA (1) UA121123C2 (enExample)
WO (1) WO2016090101A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2026052846A1 (en) 2024-09-09 2026-03-12 Synthon B.V. Pharmaceutical formulation comprising apalutamide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
AU2003292509B2 (en) * 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
SI2656842T1 (sl) * 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2012174436A1 (en) * 2011-06-15 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
JP6404217B2 (ja) * 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
NZ744456A (en) * 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014114575A1 (en) * 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists

Also Published As

Publication number Publication date
AR102924A1 (es) 2017-04-05
AU2015358493B2 (en) 2021-05-06
TW201632187A (zh) 2016-09-16
PL3226842T3 (pl) 2021-07-12
US20220151931A1 (en) 2022-05-19
AU2015358493A1 (en) 2017-06-08
US20170360707A1 (en) 2017-12-21
CO2017005573A2 (es) 2017-09-29
MX384382B (es) 2025-03-14
EA035988B1 (ru) 2020-09-09
IL252324A0 (en) 2017-07-31
UA121123C2 (uk) 2020-04-10
MA41108A (fr) 2016-06-09
MA41108B1 (fr) 2021-03-31
CN115837010A (zh) 2023-03-24
MA55404A (fr) 2022-02-02
CN106999430A (zh) 2017-08-01
ES2839128T3 (es) 2021-07-05
RS61466B1 (sr) 2021-03-31
CR20170217A (es) 2017-08-30
EP3226842B1 (en) 2020-11-25
CA2969661C (en) 2023-04-25
ES3021508T3 (en) 2025-05-27
CL2017001372A1 (es) 2018-01-05
TWI683662B (zh) 2020-02-01
BR112017011787A2 (pt) 2017-12-26
LT3226842T (lt) 2021-03-25
EP3226842A1 (en) 2017-10-11
CY1123856T1 (el) 2022-05-27
IL252324B (en) 2021-10-31
HRP20201902T1 (hr) 2021-07-23
JP2017536401A (ja) 2017-12-07
EP3842034B1 (en) 2025-02-12
SG11201704264UA (en) 2017-06-29
CA2969661A1 (en) 2016-06-09
CN115837010B (zh) 2025-03-14
KR20170086657A (ko) 2017-07-26
EA201791252A1 (ru) 2017-10-31
MD3226842T2 (ro) 2021-03-31
HUE051888T2 (hu) 2021-03-29
WO2016090101A1 (en) 2016-06-09
MX2017007201A (es) 2018-01-30
US20240293321A1 (en) 2024-09-05
PT3226842T (pt) 2020-12-23
KR102348325B1 (ko) 2022-01-06
EP3842034A1 (en) 2021-06-30
SI3226842T1 (sl) 2021-04-30
NI201700069A (es) 2017-10-31
DK3226842T3 (da) 2021-01-25

Similar Documents

Publication Publication Date Title
JP6767368B2 (ja) 抗癌性組成物
JP7174006B2 (ja) 抗癌性組成物
JP6830892B2 (ja) 抗癌性組成物
JP2019517497A (ja) 抗癌性組成物
HK40078336A (en) Anticancer compositions
EA040494B1 (ru) Противораковые композиции
BR112017011726B1 (pt) Dispersão sólida, partícula, formulação farmacêutica, processo para preparação da referida dispersão bem como combinação
HK1241764A1 (en) Anticancer compositions
HK1241764B (en) Anticancer compositions
HK1241758A1 (en) Anticancer compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200917

R150 Certificate of patent or registration of utility model

Ref document number: 6767368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250